Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.

Holtze C, Flaherty K, Kreuter M, Luppi F, Moua T, Vancheri C, Scholand MB.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180078. doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31. Review.

2.

High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes.

Ferri C, Artoni E, Sighinolfi GL, Luppi F, Zelent G, Colaci M, Giuggioli D.

Semin Arthritis Rheum. 2018 Dec;48(3):475-481. doi: 10.1016/j.semarthrit.2018.06.009. Epub 2018 Jun 24.

PMID:
30093240
3.

"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease.

Sgalla G, Walsh SLF, Sverzellati N, Fletcher S, Cerri S, Dimitrov B, Nikolic D, Barney A, Pancaldi F, Larcher L, Luppi F, Jones MG, Davies D, Richeldi L.

BMC Pulm Med. 2018 Jun 18;18(1):103. doi: 10.1186/s12890-018-0670-0.

4.

Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.

Biondini D, Balestro E, Lacedonia D, Cerri S, Milaneschi R, Luppi F, Cocconcelli E, Bazzan E, Clini E, Foschino Barbaro MP, Gregori D, Cosio MG, Saetta M, Spagnolo P.

Sci Rep. 2018 Apr 13;8(1):5961. doi: 10.1038/s41598-018-24303-4.

5.

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.

Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, Luppi F, Pesci A, Sebastiani A, Spagnolo P, Vancheri C, Balestro E, Bonifazi M, Cerri S, De Giacomi F, Della Porta R, Foschino Barbaro MP, Fui A, Pasquinelli P, Rosso R, Tomassetti S, Specchia C, Rottoli P; for the ILDINET (Interstitial Lung Diseases Italian Network).

Respiration. 2018;95(6):433-440. doi: 10.1159/000487711. Epub 2018 Mar 27.

PMID:
29587263
6.

Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?

Marchioni A, Tonelli R, Ball L, Fantini R, Castaniere I, Cerri S, Luppi F, Malerba M, Pelosi P, Clini E.

Crit Care. 2018 Mar 23;22(1):80. doi: 10.1186/s13054-018-2002-4. Review.

7.

Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis.

Pancaldi F, Sebastiani M, Cassone G, Luppi F, Cerri S, Della Casa G, Manfredi A.

Comput Biol Med. 2018 May 1;96:91-97. doi: 10.1016/j.compbiomed.2018.03.006. Epub 2018 Mar 9.

PMID:
29550468
8.

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.

Ferrara G, Luppi F, Birring SS, Cerri S, Caminati A, Sköld M, Kreuter M.

Eur Respir Rev. 2018 Feb 7;27(147). pii: 170076. doi: 10.1183/16000617.0076-2017. Print 2018 Mar 31. Review.

9.

Predicting the future of patients with idiopathic pulmonary fibrosis: another step forward.

Luppi F.

Lancet Respir Med. 2017 Dec;5(12):911-913. doi: 10.1016/S2213-2600(17)30436-8. Epub 2017 Nov 14. No abstract available.

PMID:
29150408
10.

Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study.

Tonelli R, Cocconcelli E, Lanini B, Romagnoli I, Florini F, Castaniere I, Andrisani D, Cerri S, Luppi F, Fantini R, Marchioni A, Beghè B, Gigliotti F, Clini EM.

BMC Pulm Med. 2017 Oct 10;17(1):130. doi: 10.1186/s12890-017-0476-5.

11.

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group.

Lancet Respir Med. 2017 Jul;5(7):591-598. doi: 10.1016/S2213-2600(17)30219-9. Review.

PMID:
28664861
12.

Erratum to: Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement.

Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Della Casa G, Luppi F, Ferri C.

Clin Rheumatol. 2017 Aug;36(8):1931. doi: 10.1007/s10067-017-3635-4. No abstract available.

PMID:
28444575
13.

Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement.

Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Casa GD, Luppi F, Ferri C.

Clin Rheumatol. 2017 Jun;36(6):1261-1268. doi: 10.1007/s10067-017-3601-1. Epub 2017 Mar 21. Erratum in: Clin Rheumatol. 2017 Aug;36(8):1931.

PMID:
28324200
14.

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report.

Cerri S, Sgalla G, Richeldi L, Luppi F.

J Med Case Rep. 2016 May 25;10:127. doi: 10.1186/s13256-016-0916-5.

15.

Interstitial pneumonitis with autoimmune features (IPAF): a work in progress.

Luppi F, Wells AU.

Eur Respir J. 2016 Jun;47(6):1622-4. doi: 10.1183/13993003.00690-2016. No abstract available.

16.

Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease.

Sebastiani M, Manfredi A, Cerri S, Della Casa G, Luppi F, Ferri C.

Clin Exp Rheumatol. 2016 May-Jun;34(3):564-5. Epub 2016 Feb 26. No abstract available.

PMID:
26939985
17.

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments.

De Biasi S, Cerri S, Bianchini E, Gibellini L, Persiani E, Montanari G, Luppi F, Carbonelli CM, Zucchi L, Bocchino M, Zamparelli AS, Vancheri C, Sgalla G, Richeldi L, Cossarizza A.

BMC Med. 2015 Nov 9;13:277. doi: 10.1186/s12916-015-0515-0.

18.

Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors.

Pini P, Bettua C, Orsi CF, Venturelli C, Forghieri F, Bigliardi S, Faglioni L, Luppi F, Serio L, Codeluppi M, Luppi M, Mussini C, Girardis M, Blasi E.

Infection. 2016 Apr;44(2):223-33. doi: 10.1007/s15010-015-0849-8. Epub 2015 Oct 16.

PMID:
26475482
19.

Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis.

Lococo F, Luppi F, Cerri S, Montanari G, Stefani A, Rossi G.

Lung. 2016 Feb;194(1):171-3. No abstract available.

PMID:
26475461
20.

Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature.

Ferri C, Manfredi A, Sebastiani M, Colaci M, Giuggioli D, Vacchi C, Della Casa G, Cerri S, Torricelli P, Luppi F.

Autoimmun Rev. 2016 Jan;15(1):61-70. doi: 10.1016/j.autrev.2015.09.003. Epub 2015 Sep 16. Review.

PMID:
26384526
21.

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.

Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, Tomassetti S, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M.

Respir Med. 2015 Jul;109(7):904-13. doi: 10.1016/j.rmed.2015.04.010. Epub 2015 Apr 25.

22.

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy.

Sgalla G, Cerri S, Ferrari R, Ricchieri MP, Poletti S, Ori M, Garuti M, Montanari G, Luppi F, Petropulacos K, Richeldi L.

BMJ Open Respir Res. 2015 Mar 10;2(1):e000065. doi: 10.1136/bmjresp-2014-000065. eCollection 2015.

23.

Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial.

Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, Ruggieri V, Plebani M, Barbaro MP, Spanevello A, Canonica GW, Papi A, Fabbri LM, Beghè B; FARM58J2XH Study Group.

PLoS One. 2015 Mar 11;10(3):e0118241. doi: 10.1371/journal.pone.0118241. eCollection 2015.

24.

Detection of Pneumocystis jirovecii and Aspergillus spp. DNa in bronchoalveolar lavage fluids by commercial real-time PCr assays: comparison with conventional diagnostic tests.

Orsi CF, Bettua C, Pini P, Venturelli C, La Regina A, Morace G, Luppi M, Forghieri F, Bigliardi S, Luppi F, Codeluppi M, Girardis M, Blasi E.

New Microbiol. 2015 Jan;38(1):75-84. Epub 2015 Jan 1.

25.

Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review.

Luppi F, Cerri S, Taddei S, Ferrara G, Cottin V.

Intern Emerg Med. 2015 Jun;10(4):401-11. doi: 10.1007/s11739-015-1204-x. Epub 2015 Feb 12. Review.

PMID:
25672832
26.

Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.

Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Lumetti F, Luppi F, Cerri S, Ferri C.

Reumatismo. 2015 Dec 23;67(4):149-55. doi: 10.4081/reumatismo.2015.837.

27.

Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay.

Pini P, Bettua C, Orsi CF, Venturelli C, Faglioni L, Forghieri F, Bigliardi S, Luppi F, Girardis M, Blasi E.

Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):131-136. doi: 10.1007/s10096-014-2211-y. Epub 2014 Aug 1.

PMID:
25082186
28.

Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time.

Spagnolo P, Luppi F, Maher TM, Wuyts WA, Grutters JC.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1271-2. doi: 10.1164/rccm.201209-1755LE. No abstract available.

PMID:
23725621
29.

Improvement in tubercular cavities following adjuvant treatment with endobronchial valves: a case report.

Corbetta L, Montinaro F, Rogasi PG, Luppi F, Magni C, Paiano S, Tofani A, Pistolesi M.

Int J Tuberc Lung Dis. 2013 Jun;17(6):850-1. doi: 10.5588/ijtld.12.0992. No abstract available.

PMID:
23676177
30.

Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways.

Sabatini F, Luppi F, Petecchia L, Stefano AD, Longo AM, Eva A, Vanni C, Hiemstra PS, Sterk PJ, Sorbello V, Fabbri LM, Rossi GA, Ricciardolo FL.

Eur J Pharmacol. 2013 Jun 15;710(1-3):100-9. doi: 10.1016/j.ejphar.2013.03.048. Epub 2013 Apr 12.

PMID:
23588115
31.

Prognostic role of clusterin in resected adenocarcinomas of the lung.

Panico F, Casali C, Rossi G, Rizzi F, Morandi U, Bettuzzi S, Davalli P, Corbetta L, Storelli ES, Corti A, Fabbri LM, Astancolle S, Luppi F.

Lung Cancer. 2013 Mar;79(3):294-9. doi: 10.1016/j.lungcan.2012.11.024. Epub 2012 Dec 28.

PMID:
23276503
32.

The reply.

Spagnolo P, Luppi F, Richeldi L.

Am J Med. 2013 Jan;126(1):e19. doi: 10.1016/j.amjmed.2012.09.005. No abstract available.

PMID:
23260511
33.

Genetic testing in diffuse parenchymal lung disease.

Spagnolo P, Luppi F, Cerri S, Richeldi L.

Orphanet J Rare Dis. 2012 Oct 17;7:79. doi: 10.1186/1750-1172-7-79. Review.

34.

The big clinical trials in idiopathic pulmonary fibrosis.

Luppi F, Spagnolo P, Cerri S, Richeldi L.

Curr Opin Pulm Med. 2012 Sep;18(5):428-32. doi: 10.1097/MCP.0b013e3283567ff9. Review.

PMID:
22759771
35.

Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature.

Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Vacchi C, Spagnolo P, Cerri S, Luppi F, Richeldi L, Ferri C.

Autoimmun Rev. 2013 Jan;12(3):374-9. doi: 10.1016/j.autrev.2012.06.003. Epub 2012 Jun 25. Review.

PMID:
22743031
36.

Management of idiopathic pulmonary fibrosis.

Cerri S, Spagnolo P, Luppi F, Richeldi L.

Clin Chest Med. 2012 Mar;33(1):85-94. doi: 10.1016/j.ccm.2011.11.005. Epub 2011 Dec 28. Review.

PMID:
22365248
37.

Sarcoidosis: challenging diagnostic aspects of an old disease.

Spagnolo P, Luppi F, Roversi P, Cerri S, Fabbri LM, Richeldi L.

Am J Med. 2012 Feb;125(2):118-25. doi: 10.1016/j.amjmed.2011.06.003. Review.

PMID:
22269612
38.

Co-trimoxazole effect on human alveolar macrophages of AIDS patients.

Luppi F, Covi M, Velluti G, Spagnolo P, Fabbri LM, Richeldi L.

J Biol Regul Homeost Agents. 2011 Jul-Sep;25(3):461-4.

PMID:
22023771
39.

Cellular non-specific interstitial pneumonia as a pulmonary manifestation of primary biliary cirrhosis.

Cavazza A, Rossi G, Corradi D, Luppi F, Cervi G, Spaggiari L, Falco F, Roggeri A.

Pathology. 2010;42(6):596-8. doi: 10.3109/00313025.2010.508779. No abstract available.

PMID:
20854086
40.

Non-steroid agents for idiopathic pulmonary fibrosis.

Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD003134. doi: 10.1002/14651858.CD003134.pub2. Review.

PMID:
20824834
41.

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.

Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Spagnolo P, Luppi F, Richeldi L, Ferri C.

Scand J Rheumatol. 2010 Mar;39(2):155-9. doi: 10.3109/03009740903270581.

PMID:
20059446
42.

Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed?

Luppi F, Beghé B, Richeldi L.

Am J Respir Crit Care Med. 2010 Jan 15;181(2):102-3. doi: 10.1164/rccm.200911-1668ED. No abstract available.

PMID:
20053967
43.

Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis.

Luppi F, Losi M, D'Amico R, Fabbri LM, Richeldi L.

Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(1):64-8.

PMID:
19960790
44.

Clusterin (CLU) and lung cancer.

Panico F, Rizzi F, Fabbri LM, Bettuzzi S, Luppi F.

Adv Cancer Res. 2009;105:63-76. doi: 10.1016/S0065-230X(09)05004-0. Review.

PMID:
19879423
45.

To BAL or not to BAL: is this a problem in diagnosing IPF?

Spagnolo P, Luppi F, Rossi G, Richeldi L.

Am J Respir Crit Care Med. 2009 Aug 15;180(4):379-80; author reply 380. No abstract available.

PMID:
19661255
46.

Performance of tests for latent tuberculosis in different groups of immunocompromised patients.

Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, Codeluppi M, Cocchi S, Prati F, Paci V, Meacci M, Meccugni B, Rumpianesi F, Roversi P, Cerri S, Luppi F, Ferrara G, Latorre I, Gerunda GE, Torelli G, Esposito R, Fabbri LM.

Chest. 2009 Jul;136(1):198-204. doi: 10.1378/chest.08-2575. Epub 2009 Mar 24.

PMID:
19318676
47.

EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.

Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, Bavieri M, Murer B, Meschiari E, Tamberi S, Cadioli A, Luppi F, Migaldi M, Rossi G.

Am J Clin Pathol. 2009 Apr;131(4):478-89. doi: 10.1309/AJCPH0TRMPXVZW2F.

PMID:
19289583
48.

Treatment of chronic obstructive pulmonary disease and its comorbidities.

Luppi F, Franco F, Beghé B, Fabbri LM.

Proc Am Thorac Soc. 2008 Dec 1;5(8):848-56. doi: 10.1513/pats.200809-101TH. Review.

PMID:
19017740
49.

Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation.

Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, Fabbri LM, Clini EM.

Thorax. 2008 Jun;63(6):487-92. doi: 10.1136/thx.2007.086371. Epub 2008 Jan 18.

PMID:
18203818
50.

Complex chronic comorbidities of COPD.

Fabbri LM, Luppi F, Beghé B, Rabe KF.

Eur Respir J. 2008 Jan;31(1):204-12. doi: 10.1183/09031936.00114307.

Supplemental Content

Support Center